Dr. David H. Vesole, MD
Medical Oncology (Medical Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Northwestern University Feinberg Medical School (1984)
- Years since graduation
- 42
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 506
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1984Medical school: Northwestern University Feinberg Medical School
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Medical Oncology Physician primary
NJ license 25MA08625200 -
Hematology (Internal Medicine) Physician
NJ license 25MA08625200
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hackensack University Medical Center Hackensack, NJ
- Medstar Georgetown University Hospital Washington, DC
Medical groups
- Regional Cancer Care Associates LLC (151 clinicians)
- Totowa Cancer Center (10 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 506
- Services billed
- 5,532
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Injection, epoetin alfa, (for non-esrd use), 1000 units | 1,920 | 19 |
| Established patient office or other outpatient visit, 40-54 minutes | 1,181 | 403 |
| Established patient office or other outpatient visit, 30-39 minutes | 226 | 139 |
| Injection of drug or substance under skin or into muscle | 50 | 20 |
| Established patient office or other outpatient visit, 20-29 minutes | 20 | 16 |
| New patient office or other outpatient visit, 60-74 minutes | 12 | 12 |
| New patient office or other outpatient visit, 45-59 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dexamethasone Other prescribers in Hackensack, NJ | 71 |
| Revlimid (lenalidomide) | 55 |
| Pomalyst (pomalidomide) | 50 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Hackensack, NJ | 41 |
| Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim) Other prescribers in Hackensack, NJ | 35 |
| Acyclovir Other prescribers in Hackensack, NJ | 31 |
| Gabapentin Other prescribers in Hackensack, NJ | 17 |
| Lenalidomide | 15 |
| Tramadol Hcl Other prescribers in Hackensack, NJ | 14 |
| Eliquis (apixaban) Other prescribers in Hackensack, NJ | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 13 companies reported 35 payments worth $23,608 in total to this clinician.
| Janssen Biotech, Inc. | $15,952 |
|---|---|
| Karyopharm Therapeutics Inc. | $6,065 |
| Janssen Scientific Affairs, LLC | $1,260 |
| Celgene Corporation | $82.82 |
| Genzyme Corporation | $40.67 |
| Pfizer Inc. | $38.00 |
| AbbVie Inc. | $35.25 |
| Novartis Pharmaceuticals Corporation | $27.89 |
| Compensation for services other than consulting (speaking, faculty) | $15,334 |
|---|---|
| Honoraria | $5,100 |
| Consulting Fee | $1,260 |
| Travel and Lodging | $976 |
| Food and Beverage | $838 |
| Education | $99.99 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $5,288 |
| Janssen Biotech, Inc. Nov 21, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,583 |
| Janssen Biotech, Inc. Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,583 |
| Karyopharm Therapeutics Inc. Nov 5, 2025 | Honoraria XPOVIO · Oncology | $4,250 |
| Janssen Biotech, Inc. Aug 12, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $881 |
| Karyopharm Therapeutics Inc. Nov 5, 2025 | Travel and Lodging XPOVIO · Oncology · travel to Red Bank, NJ · in-kind | $865 |
| Karyopharm Therapeutics Inc. Apr 23, 2025 | Honoraria XPOVIO · Oncology | $850 |
| Janssen Scientific Affairs, LLC Jan 15, 2025 | Consulting Fee | $840 |
| Janssen Scientific Affairs, LLC Mar 31, 2025 | Consulting Fee | $420 |
| Janssen Biotech, Inc. Jul 15, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $99.99 |
All 14 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Janssen Biotech, Inc. Dec 22, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Little Falls, NJ | $37.80 |
| Janssen Biotech, Inc. Dec 22, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Little Falls, NJ | $23.06 |
| Janssen Biotech, Inc. Nov 21, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,583 |
| Karyopharm Therapeutics Inc. Nov 5, 2025 | Honoraria XPOVIO · Oncology | $4,250 |
| Karyopharm Therapeutics Inc. Nov 5, 2025 | Travel and Lodging XPOVIO · Oncology · travel to Red Bank, NJ · in-kind | $865 |
| Janssen Biotech, Inc. Oct 29, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Cedar Grove, NJ | $26.60 |
| Janssen Biotech, Inc. Oct 29, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Cedar Grove, NJ | $23.82 |
| Janssen Biotech, Inc. Sep 30, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $4,583 |
| Janssen Biotech, Inc. Aug 12, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $881 |
| Janssen Biotech, Inc. Jul 25, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $5,288 |
| Janssen Biotech, Inc. Jul 15, 2025 | Education DARZALEX; TALVEY; TECVAYLI · Oncology · in-kind | $99.99 |
| Karyopharm Therapeutics Inc. Apr 23, 2025 | Honoraria XPOVIO · Oncology | $850 |
| Janssen Scientific Affairs, LLC Mar 31, 2025 | Consulting Fee | $420 |
| Janssen Scientific Affairs, LLC Jan 15, 2025 | Consulting Fee | $840 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 3 companies. The companies reported $373,315 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Genzyme Corporation · Active, not recruiting · NCT06356571 - A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma
Genzyme Corporation · Recruiting · NCT06630806 - A randomized 2ARM phase 3 study of elranatamab PF06863135 versus lenalidomide in patients with newly diagnosed multiple myeloma after undergoing autologous stemcell transplantation
Pfizer Inc. - MAGNETISMM3 an openlabel multicenter nonrandomized phase 2 study of elranatamab PF06863135 monotherapy in participants with multiple myeloma who are refractory to at least one proteasome inhibitor one immunomodulatory…
Pfizer Inc. - A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous St…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.